PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11029783-8	2000	Docetaxel increased IL-6 levels in both serum and KPL-4 tumors, but combined treatment with docetaxel and 5"-DFUR resulted not only in a potent antitumor effect but also in a drastic decrease of serum IL-6 levels.	Docetaxel	0-9	interleukin 6	Homo sapiens	20-24	
19014338-9	2009	Elevated IL-6 levels and reductions in IL-6 levels early in treatment may reflect ultimate clinical response to docetaxel-based regimens.	Docetaxel	112-121	interleukin 6	Homo sapiens	9-13	
19014338-9	2009	Elevated IL-6 levels and reductions in IL-6 levels early in treatment may reflect ultimate clinical response to docetaxel-based regimens.	Docetaxel	112-121	interleukin 6	Homo sapiens	39-43	
12085250-13	2002	The present study indicates that patients responded to treatment of advanced breast cancer with single-agent paclitaxel or docetaxel leads to an increase in serum IFN-gamma, IL-2, IL-6, GM-CSF cytokine levels and enhancement of PBMC NK and LAK cell activity, while they both lead to a decrease of acute phase serum cytokine levels of IL-1 and TNF-alpha.	Docetaxel	123-132	interleukin 6	Homo sapiens	180-184	
11710628-0	2001	Combined effects of docetaxel and fluoropyrimidines on tumor growth and expression of interleukin-6 and thymidine phosphorylase in breast cancer xenografts.	Docetaxel	20-29	interleukin 6	Homo sapiens	86-99	
11710628-9	2001	In addition, combined treatment with docetaxel and oral fluoropyrimidines may decrease serum IL-6 levels and may ameliorate IL-6-induced cancer cachexia.	Docetaxel	37-46	interleukin 6	Homo sapiens	93-97	
11710628-9	2001	In addition, combined treatment with docetaxel and oral fluoropyrimidines may decrease serum IL-6 levels and may ameliorate IL-6-induced cancer cachexia.	Docetaxel	37-46	interleukin 6	Homo sapiens	124-128	
21214673-3	2011	Changes in the growth and sensitivity to docetaxel in PC3/sh-IL6 were compared with those in PC3 transfected with control vector alone (PC3/Co).	Docetaxel	41-50	interleukin 6	Homo sapiens	61-64	
21214673-6	2011	Despite the higher sensitivity of PC3/sh-IL6 to docetaxel than that of PC3/Co, the secretion of IL-6 by both cell lines was increased after treatment with docetaxel due to the formation of positive autocrine loops between these cell lines and NFkappaB signaling pathways.	Docetaxel	48-57	interleukin 6	Homo sapiens	41-44	
21214673-6	2011	Despite the higher sensitivity of PC3/sh-IL6 to docetaxel than that of PC3/Co, the secretion of IL-6 by both cell lines was increased after treatment with docetaxel due to the formation of positive autocrine loops between these cell lines and NFkappaB signaling pathways.	Docetaxel	155-164	interleukin 6	Homo sapiens	41-44	
21214673-6	2011	Despite the higher sensitivity of PC3/sh-IL6 to docetaxel than that of PC3/Co, the secretion of IL-6 by both cell lines was increased after treatment with docetaxel due to the formation of positive autocrine loops between these cell lines and NFkappaB signaling pathways.	Docetaxel	155-164	interleukin 6	Homo sapiens	96-100	
21214673-7	2011	Furthermore, combined treatment with the proteasome inhibitor bortezomib, which completely inhibited the docetaxel-induced IL-6 secretion via the inactivation of NFkappaB signaling, resulted in the marked sensitization of these cell lines to docetaxel both in vitro and in vivo.	Docetaxel	105-114	interleukin 6	Homo sapiens	123-127	
21214673-8	2011	These findings suggest that suppressed IL-6 secretion using shRNA, either alone or in combination with docetaxel and bortezomib, could be a useful therapeutic strategy against androgen-independent prostate cancer.	Docetaxel	103-112	interleukin 6	Homo sapiens	39-43	
12085250-12	2002	More specifically, docetaxel demonstrated a more pronounced effect on enhancing MLR, NK, LAK activity and IFN-gamma, IL-2, IL-6, and GM-CSF levels, as well as caused more potent reduction in IL-1 and TNF-alpha levels when compared to paclitaxel.	Docetaxel	19-28	interleukin 6	Homo sapiens	123-127	
11029783-8	2000	Docetaxel increased IL-6 levels in both serum and KPL-4 tumors, but combined treatment with docetaxel and 5"-DFUR resulted not only in a potent antitumor effect but also in a drastic decrease of serum IL-6 levels.	Docetaxel	92-101	interleukin 6	Homo sapiens	201-205	
28259909-7	2017	CACNAD2A3, GDF5 and IL6 were upregulated and NANOG was downregulated in the MCF7 breast cancer cells expressing increased levels of PAR4 after treatment with docetaxel, likely indicating inactivation of the WNT/beta-catenin pathway.	Docetaxel	158-167	interleukin 6	Homo sapiens	20-23	
34862831-9	2022	EEP + DTX exerted no cytotoxic effects on monocytes and stimulated HLA-DR expression, TNF-alpha, and IL-6 production, exerted an immunorestorative action in the fungicidal activity, and reduced the oxidative stress.	Docetaxel	6-9	interleukin 6	Homo sapiens	101-105	
29565447-21	2018	Univariate and multivariate analyses revealed that age, CA125, interstitial IL-6 expression and cytoreduction satisfaction were closely related to the sensitivity of the TP (docetaxel plus cisplatin or carbopatin) regimen in ovarian cancer (P<0.05).	Docetaxel	174-183	interleukin 6	Homo sapiens	76-80	
34293716-10	2021	Consistent with this model, the overexpression of IL-6 reversed the OGFRP1 knockdown-mediated reductions in docetaxel and paclitaxel IC50 values for these PC cells.	Docetaxel	108-117	interleukin 6	Homo sapiens	50-54	
31412584-3	2019	Docetaxel or vinorelbine inhibits proliferation and stimulates the differentiation of breast preadipocytes, by increasing C/EBPalpha and PPARgamma expression and by downregulating tumor necrosis factor alpha (TNFalpha), interleukin 6 (IL-6), and IL-11 expression.	Docetaxel	0-9	interleukin 6	Homo sapiens	220-233	
31412584-3	2019	Docetaxel or vinorelbine inhibits proliferation and stimulates the differentiation of breast preadipocytes, by increasing C/EBPalpha and PPARgamma expression and by downregulating tumor necrosis factor alpha (TNFalpha), interleukin 6 (IL-6), and IL-11 expression.	Docetaxel	0-9	interleukin 6	Homo sapiens	235-239	
26528857-8	2015	In line with the above findings, treatment with either IL-3 or IL-6 or IL-11 decreased the chemosensitivity to docetaxel while treatment with either IL-10 or IL-24 increased the sensitivity of docetaxel chemotherapy.	Docetaxel	111-120	interleukin 6	Homo sapiens	63-67	
26194374-6	2016	In the TSU-68 plus docetaxel group, PFS showed significant association with fold changes in CRP (p=0.001), IL-6 (p < .001), PDGF-BB (p=0.02), and VEGF (p=0.047) following the first treatment cycle.	Docetaxel	19-28	interleukin 6	Homo sapiens	107-111	
24939178-7	2014	Together, our data provide a novel explanation that high level of IL6 stimulated SOD2 expression that, at least partially, contributed to the low level of ROS that would likely result in a sustained increase in the expression of IGF-1R through abolishment of beta-arrestin1 in docetaxel resistant cells.	Docetaxel	277-286	interleukin 6	Homo sapiens	66-69	
24939178-0	2014	Regulation of SOD2 and beta-arrestin1 by interleukin-6 contributes to the increase of IGF-1R expression in docetaxel resistant prostate cancer cells.	Docetaxel	107-116	interleukin 6	Homo sapiens	41-54	
23038213-0	2013	Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.	Docetaxel	49-58	interleukin 6	Homo sapiens	27-40